Genedrive Share Discussion Threads

[swerves1] 09/2/2021 11:56

And a signed partnership now with a multi billion dollar company. The share price could go mental soon...

[bunz3] 09/2/2021 11:56

more than covid testing




Genedrive HCV ID Kit demonstrates high clinical accuracy in India study

Hepatitis C virus testing kit reveals 100% sensitivity and specificity when compared to Abbott Real time HCV test



Genedrive plc (AIM:GDR), the near patient molecular diagnostics company, announces the publication of the study data for the 'Evaluation of the Point of Care Molecular Diagnostic Genedrive HCV ID Kit for the detection of HCV RNA in clinical samples'.



The study1 was led by Dr Ekta Gupta at ILBS, New Delhi, India. The objective of the study was to determine the diagnostic accuracy of the Genedrive HCV ID Kit, as a confirmatory test for seropositive hepatitis C virus (HCV) patients in Indian demographic settings.



Details of the study are published online here: [...]



The diagnostic accuracy of the Genedrive HCV ID Kit was evaluated by comparing the test with the Abbott Real time HCV test on the lab-based Abbott m2000 platform in an Indian demographic and across a range of different genotypes, to ensure suitability for introduction of the product to the Indian population. In India the circulation of HCV genotype is predominantly genotypes 3 and 1 with live infections of HCV estimated at between 6-12 million2.



150 HCV RNA positive and 170 HCV RNA negative samples were tested using both methods. The comparison revealed 100% sensitivity (95% CI 97.9 - 100%) and 100% specificity (95% CI 97.9 - 100%). The overall diagnostic accuracy was 100% (95% CI 98.9 - 100%).



Overall, the study demonstrates that the Genedrive HCV ID Kit is suitable for use in India and can be used for decentralised testing of HCV thereby reducing the loss of patients to follow up.



David Budd, CEO of genedrive plc, said: "These excellent clinical results for our HCV assay further validate the applicability of the test for a decentralised setting. India is a key target market for our assay and we are excited about the commercial prospects in the region."

[bunz3] 09/2/2021 11:45

Hooded Claw

part of reason I invested here was when i read that no Debt as well as the cash in Bank ,as well as the low share price .

[hooded claw] 09/2/2021 11:43

QS, yes from a while back and converted at a low share price.But the silver lining for that was no debt with cash in the bank.

[hooded claw] 09/2/2021 11:38

They don't need extra money to ramp up production either.Then can produce 240,000 a day running 3 shifts and 1.2m a week over 5 days.With revenue of £10 a bead that is £12m a week at full capacity. NDA currently covers increasing production with BC so draw your own conclusions. All this just for the beads side of the business and some are sitting waiting for the chart to form a handle.

[losses] 09/2/2021 11:32

Non stopping this... would be good to see 150 this week if not end of today at this rate

[bunz3] 09/2/2021 11:30

so undervalued

[qs99] 09/2/2021 11:30

BGF are early stage funders are they not, so maybe been in for a while and selling down, leaving rest in for the ride?

DYOR

[maxplus2] 09/2/2021 11:28

Why did then BGF reduced the holding?

[babbler] 09/2/2021 11:27

Go buy ocado shares then. Billions mcap and made a 40m loss

[19th hole] 09/2/2021 11:21

Finncap have been sat either at the top of the bid or close to it all day Max. I don't think they would be looking for stock if there was a placing

[bunz3] 09/2/2021 11:19

THE Beckman Coulter rns

Changed this share

some share boards now discussing Take over ,

personly hope not yet ,£10 or £12 a share in future months will not surprise me

having seen how ncyt moved up

[hooded claw] 09/2/2021 11:19

Maxplus, don't buy then. Anyone with a calculator can work out what the deal is worth to GDR and it is multiples of current price.

[maxplus2] 09/2/2021 11:15

£8.2m year end as per Nov 2020 results. We had similar situation last year and I am just concerned

[seball] 09/2/2021 11:13

Massive Buying volume, seller cleared. Blue sky to first stop 200p then onto 500p once sales news starts coming in. Strong Buy

[qs99] 09/2/2021 11:09

Still sub £80m market cap, so much more to come IMO....enjoying the ride....DYOR

[hooded claw] 09/2/2021 11:01

Maxplus, perhaps you should read cash position in last update ?

[bunz3] 09/2/2021 11:00

When first USA orders are seen how high is this likely to move up

[stumbleupon] 09/2/2021 10:55

I hope that something similar happens here

[bunz3] 09/2/2021 10:53

buying pressure looks to be building up more

each day now getting closer to mid mid February

[bunz3] 09/2/2021 10:47

buy quote now moved back up to 130 ,

so many buys going through ,continuing to push this up more

not even 11,am yet

and so many buys going through

[bunz3] 09/2/2021 10:37

sells being mopped up so soon by these buyers

so many look to have read this rns
even this part of rns

Distribution agreement with Beckman Coulter Life Sciences for COVID-19 PCR testing



genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into a distribution agreement with Beckman Coulter Life Sciences ("Beckman Coulter") for its Genedrive® 96 SARS-CoV-2 Kit. The agreement enables Beckman Coulter to sell and distribute genedrive's high-throughput COVID-19 PCR Kit in the United States and Europe for use on upper respiratory viral samples. The agreement is the result of the collaboration agreement announced in August 2020, under which the companies worked to develop and validate a fully automated PCR process for Beckman Coulter's Biomek automated workstation in conjunction with its RNAdvance Viral XP extraction kit.



The Genedrive® 96 SARS-CoV-2 test is ideally suited for use on the high throughput robotic Biomek i7 instrument. The ready-to-go nature of the test removes many of the fluid dispensing steps required in competitor assays, increasing the overall throughput of the Biomek compared to using a liquid reagent based test formulation. Full automation of the overall PCR workflow can allow laboratories to run large numbers of tests over extended working hours or workstation platforms. Beckman Coulter estimates that this new turnkey solution could process circa 1,000 PCR samples per Biomek workstation installed during a standard 8-hour working day, using just a 0.5 full-time-equivalent in technician time for processing.

.

[bunz3] 09/2/2021 10:34

so strong of buying as more pick up shares as getting closer to mid month